The Latest
- Mar 12, 2021MedX Health Corp. Announces Retirement of Board Members
- Mar 10, 2021MedX Health Corp. and Empower Clinics Inc. to Pilot World-Class Teledermatology Screening Platform at Select Ontario Integrated Health Centres
- Mar 02, 2021MedX Health Corp. Announces the Appointment of a Sales and Marketing Director for Europe, Middle East, Africa (EMEA)
- Feb 25, 2021MedX Announces Final Closing of $4 Million Convertible Debenture Loan Notes Non-brokered Private Placement
- Feb 01, 2021MedX Announces Closings of first $2.5 million of Convertible Debenture Loan Notes, and anticipates further closings up to $1.5 million
Reports and Filings
- May 23, 2017Interim Financial Statements/Report - English
- May 01, 2017MD&A - English
- May 01, 2017Audited Annual Financial Statements - English
- Nov 28, 2016MD&A - English
- Nov 28, 2016Interim Financial Statements/Report - English
- Aug 26, 2016Interim Financial Statements/Report - English
- May 30, 2016Interim Financial Statements/Report - English
- May 30, 2016MD&A - English
- Apr 29, 2016Audited Annual Financial Statements - English
- Apr 29, 2016MD&A - English
MedX is committed to technology that is safe and effective.
The safety and effectiveness for patients is our first priority. SIAcopy is rapid, patient-friendly, accurate, easy to use, and practice-friendly. SIAscopy has been used for over 12 years and is supported by over 15 published clinical studies and 24 in vivo clinical posters. MedX Health designs, develops and distributes innovative imaging and software technologies that have been tested for safety and effectiveness and have been cleared and licensed for use in Canada, European Union, and Australia.
The technology has gone through stringent testing and it has been cleared for sale by the following regulatory bodies: Health Canada, CE and ARTG.